Adaptive Biotechnologies has launched a test that identifies T cells activated by Borrelia burgdorferi, the bacterium that causes Lyme disease.
T-Detect Lyme, a blood test that aims to diagnose Lyme disease sooner, uses Adaptive's sequencing capabilities and Microsoft's cloud-scale AI (artificial intelligence) to characterize the T-cell repertoire and identify a clinical signal for disease.
T-Detect detects an immune response by leveraging the body's unique T-cell response to disease-associated antigens.
The test is available to patients with a prescription through a qualified healthcare professional.
